As HER3 is poorly expressed in immune cells, this reduction is likely initiated by CDX-3379 inhibition of cancer-driving PI3K-AKT-mTOR activity in HNSCC cells, which may in turn result in reduced chemokine and cytokine secretion in cancer cells directly, for example through a translational control46, thus disrupting a complex immune suppressive cross talk among immune cells in the TIME. The gene discussed is ERBB3; the disease is head and neck squamous cell carcinoma.